ADRA2C encodes the alpha-2C adrenergic receptor, a G protein-coupled receptor that responds to catecholamines and activates the G(i/o) signaling pathway, leading to adenylyl cyclase inhibition and regulation of various physiological processes 1. The receptor mediates presynaptic feedback inhibition of neurotransmitter release from noradrenergic nerve terminals, specifically modulating neurotransmission at lower levels of nerve activity compared to ADRA2A 1. ADRA2C shows differential brain expression patterns in psychiatric disorders, with upregulation observed in schizophrenia patients regardless of antipsychotic treatment, regulated through epigenetic mechanisms including histone modifications 2. Clinically, ADRA2C genetic variants demonstrate significant therapeutic relevance: the deletion polymorphism (Del322-325) is associated with reduced risk of life-threatening catecholamine-induced cardiomyopathy in pheochromocytoma patients and lower incidence of ventricular fibrillation during myocardial infarction 34. The receptor also plays roles in cancer progression and maternal stress responses affecting embryo implantation 56. Despite evidence for pharmacogenomic associations with beta-blocker therapy, current evidence remains insufficient for clinical therapeutic recommendations 7.